| Company Name: |
Suzhou Rovathin Foreign Trade Co.,Ltd
|
| Tel: |
0512-65816829 18662214788 |
| Email: |
info@rovathin.com.cn |
| Products Intro: |
Product Name:6,8-dibromo-2-(4-bromophenyl)-3-nitro-2H-chromene
CAS:1685280-21-0
Package:100g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:DMH-25;DMH25,DMH 25
CAS:1685280-21-0
Purity:99.05% Package:1 mg;10 mg;100 mg;2 mg;25 mg;5 mg;50 mg
|
|
| Product Name: | DMH-25 | | Synonyms: | DMH-25;6,8-dibromo-2-(4-bromophenyl)-3-nitro-2H-chromene;DMH25,DMH 25;2H-1-Benzopyran, 6,8-dibromo-2-(4-bromophenyl)-3-nitro- | | CAS: | 1685280-21-0 | | MF: | C15H8Br3NO3 | | MW: | 489.94 | | EINECS: | | | Product Categories: | | | Mol File: | 1685280-21-0.mol |  |
| | DMH-25 Chemical Properties |
| Boiling point | 537.7±50.0 °C(Predicted) | | density | 2.12±0.1 g/cm3(Predicted) |
| | DMH-25 Usage And Synthesis |
| Description | DMH25 is a novel covalent and potent mTOR inhibitor, which shows in vivo antitumor activity against triple-negative breast cancer cells. ation. DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. |
| | DMH-25 Preparation Products And Raw materials |
|